Go Deep
Neuland Laboratories Limited
Neuland Laboratories Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 15,704 | 56.5 | 14.99 | 0.16 | 21,905.00 |
| Oct 2026 | 15,549 | 53.8 | 14.30 | 0.16 | 20,890.00 |
Neuland Laboratories Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 6,415,771,000.0 | 7,762,503,000.0 | 4,397,093,000.0 | 5,142,731,000.0 |
| Net Profit | 1,476,731,000.0 | 2,126,726,000.0 | 405,719,000.0 | 968,539,000.0 |
| EPS | 115.1 | 165.8 | 31.6 | 75.5 |
Neuland Laboratories Limited Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 19,321,190,000.0 | 14,343,821,000.0 | 15,156,631,000.0 | 11,608,985,000.0 |
| Net Profit | 3,639,984,000.0 | 2,601,081,000.0 | 3,000,789,000.0 | 1,635,176,000.0 |
| EPS | 283.7 | 202.7 | 233.9 | 127.5 |
Neuland Laboratories Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 29,301,377,000.0 | 21,798,816,000.0 | 18,325,610,000.0 | 15,797,645,000.0 | — |
| Total Liabilities | 10,556,648,000.0 | 6,550,753,000.0 | 5,498,562,000.0 | 5,856,680,000.0 | — |
| Total Equity | 18,744,729,000.0 | 15,248,063,000.0 | 12,827,048,000.0 | 9,940,965,000.0 | — |
Owes vs Owns
Neuland Laboratories Limited owed ₹0.36 for every ₹1 it owned in Mar 2026, down from ₹0.37 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.36× | 0.30× | 0.30× | 0.37× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Neuland Laboratories Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 11.1%Receivables 18.5%Inventory 17.4%Fixed assets (tangible) 39.0%Intangible assets 9.8%Other assets 4.1%
How it's funded — Mar 2026
Short-term debt 1.2%Long-term debt 5.5%Payables 9.2%Other liabilities 20.1%Shareholders' equity 64.0%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 326.7 | 352.2 | 102.6 | 45.4 |
| Receivables | 541.4 | 315.7 | 373.5 | 361.8 |
| Inventory | 510.3 | 385.8 | 350.4 | 279.2 |
| Fixed assets (tangible) | 1,143.0 | 733.4 | 589.8 | 499.8 |
| Intangible assets | 285.7 | 284.3 | 281.9 | 280.8 |
| Long-term investments | 2.0 | 1.5 | 1.3 | 0.5 |
| Other assets | 121.1 | 107.0 | 133.0 | 112.2 |
| Liabilities & equity | ||||
| Short-term debt | 35.7 | 45.3 | 37.6 | 47.3 |
| Long-term debt | 160.9 | 90.7 | 44.9 | 74.2 |
| Payables | 269.1 | 252.2 | 192.0 | 171.0 |
| Other liabilities | 589.9 | 266.9 | 275.4 | 293.2 |
| Shareholders' equity | 1,874.5 | 1,524.8 | 1,282.7 | 994.1 |
| Net tangible assets | 1,588.7 | 1,240.5 | 1,000.8 | 713.3 |
Neuland Laboratories Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 3,466,804,000.0 | 3,174,042,000.0 | 2,611,767,000.0 | 2,372,119,000.0 | — |
| Investing Activities | -4,237,329,000.0 | -2,981,559,000.0 | -1,496,868,000.0 | -614,985,000.0 | — |
| Financing Activities | 209,754,000.0 | 249,610,000.0 | -692,818,000.0 | -1,357,958,000.0 | — |